Quick Answer
VACCINEX, INC. reported Total Revenue of $601.0 thousand for fiscal year 2024.
VACCINEX, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $601.0K +5.4% |
$570.0K +107.3% |
$275.0K -69.4% |
$900.0K +44.0% |
$625.0K +19.5% |
$523.0K -27.8% |
| Revenue (ASC 606) | $601.0K +5.4% |
$570.0K +107.3% |
$275.0K -69.4% |
$900.0K +44.0% |
$625.0K +19.5% |
$523.0K -27.8% |
| Net Income | -$18.63M +8.0% |
-$20.25M -2.2% |
-$19.82M +11.5% |
-$22.38M +22.4% |
-$28.85M +9.5% |
-$31.86M -7.9% |
| Diluted EPS | -$8.88 +79.7% |
-$43.68 +55.5% |
-$98.05 -12470.5% |
-$0.78 | — | — |
| Total Assets | $2.60M -28.5% |
$3.63M -54.5% |
$7.98M -19.0% |
$9.84M -15.9% |
$11.70M +154.2% |
$4.60M -79.1% |
| Cash and Equivalents | $1.11M -27.9% |
$1.53M -76.0% |
$6.39M -25.6% |
$8.59M -18.9% |
$10.60M +281.7% |
$2.78M -50.6% |
| Long-Term Debt | $0.00 -100.0% |
$26.0K -74.3% |
$101.0K -42.3% |
$175.0K -84.6% |
$1.13M | — |
| Stockholders Equity | -$2.49M -7.7% |
-$2.31M -144.5% |
$5.19M -29.9% |
$7.41M +127.9% |
-$26.57M -1.3% |
-$26.24M -204.3% |
| R&D Expense | $12.54M -24.3% |
$16.57M +18.6% |
$13.98M -18.5% |
$17.16M -20.4% |
$21.55M -16.1% |
$25.67M +14.8% |
| Operating Income | -$18.73M +18.1% |
-$22.89M -15.0% |
-$19.91M +11.5% |
-$22.49M +20.6% |
-$28.33M +11.5% |
-$32.02M -17.4% |
| Shares Outstanding | 2.68M +199.9% |
892,617 +275.8% |
237,527 -99.2% |
30.80M +37.6% |
22.39M +50.4% |
14.89M +29.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $52.0K | +160.0% | -77.6% |
| Revenue (ASC 606) | September 30, 2024 | $52.0K | +160.0% | -77.6% |
| Net Income | September 30, 2024 | -$5.73M | -16.7% | -1.8% |
| Diluted EPS | September 30, 2024 | -$2.83 | +81.4% | +8.7% |
| Total Assets | September 30, 2024 | $4.85M | +89.8% | +105.1% |
| Cash and Equivalents | September 30, 2024 | $2.91M | +2188.2% | +1147.2% |
| Long-Term Debt | March 31, 2024 | $6.0K | -92.7% | -76.9% |
| Stockholders Equity | September 30, 2024 | -$1.32M | +65.9% | +53.9% |
| R&D Expense | September 30, 2024 | $3.17M | -27.3% | -18.1% |
| Operating Income | September 30, 2024 | -$4.55M | +22.0% | +20.4% |
| Shares Outstanding | September 30, 2024 | 2.60M | -46.5% | +64.0% |
- VACCINEX, INC. reported Total Revenue of $601.0 thousand for fiscal year 2024.
- VACCINEX, INC. showed an increase of +5.4% in Total Revenue compared to the prior fiscal year.
- VACCINEX, INC. reported Revenue (ASC 606) of $601.0 thousand for fiscal year 2024.
- VACCINEX, INC. showed an increase of +5.4% in Revenue (ASC 606) compared to the prior fiscal year.
- VACCINEX, INC. reported Net Income of -$18.63 million for fiscal year 2024.
- VACCINEX, INC. showed an increase of +8.0% in Net Income compared to the prior fiscal year.
- VACCINEX, INC. reported Diluted EPS of $8.88 per share (loss) for fiscal year 2024.
- VACCINEX, INC. showed an increase of +79.7% in Diluted EPS compared to the prior fiscal year.
- VACCINEX, INC. reported Total Assets of $2.60 million for fiscal year 2024.
- VACCINEX, INC. showed a decrease of -28.5% in Total Assets compared to the prior fiscal year.
- VACCINEX, INC. reported Cash and Equivalents of $1.11 million for fiscal year 2024.
- VACCINEX, INC. showed a decrease of -27.9% in Cash and Equivalents compared to the prior fiscal year.
- VACCINEX, INC. reported Long-Term Debt of $0.00 for fiscal year 2024.
- VACCINEX, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- VACCINEX, INC. reported Stockholders Equity of -$2.49 million for fiscal year 2024.
- VACCINEX, INC. showed a decrease of -7.7% in Stockholders Equity compared to the prior fiscal year.
- VACCINEX, INC. reported R&D Expense of $12.54 million for fiscal year 2024.
- VACCINEX, INC. showed a decrease of -24.3% in R&D Expense compared to the prior fiscal year.
- VACCINEX, INC. reported Operating Income of -$18.73 million for fiscal year 2024.
- VACCINEX, INC. showed an increase of +18.1% in Operating Income compared to the prior fiscal year.
- VACCINEX, INC. reported Shares Outstanding of 2.68 million shares for fiscal year 2024.
- VACCINEX, INC. showed an increase of +199.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: